A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors.

Summary

The purpose of the study is to test the safety and dosing of \[177Lu\]Lu-FF58, a radioligand therapy for patients with advanced or metastatic tumors that express proteins known as integrins: alpha-v beta-3 integrin (αvβ3) and alpha-v beta-5 integrin (αvβ5). The study will also further characterize the radioligand imaging agent \[68Ga\]Ga-FF58 including its ability to identify tumor lesions and its safety profile.

Timeline

Start

2023-10-06

Primary completion

2024-12-13

Completion

2024-12-13

Outcome

Outcome not reported

Stopped: “The decision was not based on any safety concerns”

Drugs

Indications